<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pharmateca</journal-id><journal-title-group><journal-title xml:lang="en">Pharmateca</journal-title><trans-title-group xml:lang="ru"><trans-title>Фарматека</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2073-4034</issn><issn publication-format="electronic">2414-9128</issn><publisher><publisher-name xml:lang="en">Bionika Media</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">295234</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">FEATURES OF MANAGEMENT OF PREGNANCY IN WOMEN WITH DIFFUSE TOXIC GOITER</article-title><trans-title-group xml:lang="ru"><trans-title>ОСОБЕННОСТИ ВЕДЕНИЯ БЕРЕМЕННОСТИ У ЖЕНЩИН С ДИФФУЗНЫМ ТОКСИЧЕСКИМ ЗОБОМ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Lovkova</surname><given-names>Yu. S</given-names></name><name xml:lang="ru"><surname>Ловкова</surname><given-names>Ю. С</given-names></name></name-alternatives><bio xml:lang="en"><p>Endocrinologist, Postgraduate Student at the Department of Endocrinology n.a. Acad. V.G. Baranov</p></bio><bio xml:lang="ru"><p>врач-эндокринолог, аспирант кафедры эндокринологии им. акад. В.Г. Баранова</p></bio><email>juliadoktor@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Vorokhobina</surname><given-names>N. V</given-names></name><name xml:lang="ru"><surname>Ворохобина</surname><given-names>Н. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kuznetsova</surname><given-names>A. V</given-names></name><name xml:lang="ru"><surname>Кузнецова</surname><given-names>А. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">North-Western State Medical University n.a. I.I. Mechnikov of RMH</institution></aff><aff><institution xml:lang="ru">Северо-Западный государственный медицинский университет им. И.И. Мечникова Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2018-04-15" publication-format="electronic"><day>15</day><month>04</month><year>2018</year></pub-date><volume>25</volume><issue>4</issue><issue-title xml:lang="en">NO4 (2018)</issue-title><issue-title xml:lang="ru">№4 (2018)</issue-title><fpage>32</fpage><lpage>39</lpage><history><date date-type="received" iso-8601-date="2023-02-27"><day>27</day><month>02</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2018, Bionika Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2018, ООО «Бионика Медиа»</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="en">Bionika Media</copyright-holder><copyright-holder xml:lang="ru">ООО «Бионика Медиа»</copyright-holder></permissions><self-uri xlink:href="https://journals.eco-vector.com/2073-4034/article/view/295234">https://journals.eco-vector.com/2073-4034/article/view/295234</self-uri><abstract xml:lang="en"><p>Euthyroid status is a necessary optimal condition for a favorable outcome of pregnancy in women with diffuse toxic goiter (DTG), which is considered as the most common cause of thyrotoxicosis during this period, and has a negative effect on the course and outcome of pregnancy. Different opinions existing in the scientific literature about the tactics of pregnancy management in women with DTG determine the relevance of this topic. Methods. The results of a study on the use of thyreostatic therapy in 67 pregnant women with DTG are presented. The main methods of evaluation in the study included thyroid echography in women throughout pregnancy and in newborns on the 4th-7th day of life, as well as determination of the thyroid-stimulating hormone (TSH), free thyroxine (Free T4) and TSH receptor antibodies (anti-TSHR) levels in the blood of pregnant women and in umbilical cord blood. Results. The results indicate a higher incidence of complications of pregnancy (early toxicosis - 83%, threatening miscarriage - 94%, placental insufficiency - 55%, gestosis -100%, fetal hypotrophy - 88%) and childbirth (premature delivery - 33%, fetal hypoxia - 44%) in women with thyrotoxicosis. The high incidence of goiter in newborns (more than 83%) is associated with the negative effect of transplacental transfer of thyreostatic drugs and anti - TSHR on the volume and functional status of thyroid gland in newborns. An important factor determining the need to optimize the doses of thyreostatic drugs is the high risk of developing neonatal hypothyroidism (in 53% of newborns). Conclusion. The high incidence of subclinical hypothyroidism in newborns (53%) from mothers with DTG requires the optimization of thyroid doses prescribed for the treatment of DTG during pregnancy.</p></abstract><trans-abstract xml:lang="ru"><p>Эутиреоидное состояние - необходимое оптимальное условие благоприятного исхода беременности у женщин с диффузным токсическим зобом (ДТЗ), который считается наиболее частой причиной развития тиреотоксикоза в этот период, оказывает негативное влияние на течение и исход беременности. Существующие в научной литературе различные мнения о тактике ведения беременности у женщин с ДТЗ определяют актуальность данной темы. Методы. Представлены результаты исследования по применению тиреостатической терапии 67 беременных женщин с ДТЗ. В качестве основных методов исследования применялись эхография щитовидной железы (ЩЖ) у женщин на протяжении всей беременности и у новорожденных на 4-7-е сутки жизни, а также исследование содержания тиреотропного гормона (ТТГ), свободного тироксина (свТ4) и антител к рецептору ТТГ (АТ-рТТГ) в крови беременных женщин и в пуповинной крови. Результаты. Полученные результаты свидетельствуют о более высокой частоте осложнений беременности (ранний токсикоз - 83%, угроза прерывания беременности - 94%, плацентарная недостаточность -55%, гестоз - 100%, гипотрофия плода - 88%) и родов (преждевременные роды - 33%, гипоксия плода - 44%) у женщин с тиреотоксикозом. Высокая частота развития зоба у новорожденных (более 83%) связана с негативным влиянием трансплацентарного переноса тиреостатических препаратов и АТ-рТТГ на объем и функциональное состояние ЩЖ новорожденных. Важным фактором, определяющим необходимость оптимизации доз тиреостатических препаратов, служит высокий риск развития неонатального гипотиреоза (у 53% новорожденных). Заключение. Высокая частота субклинического гипотиреоза у новорожденных (53%) от матерей с ДТЗ требует оптимизации доз тиреостатиков, назначаемых для лечения ДТЗ во время беременности.</p></trans-abstract><kwd-group xml:lang="en"><kwd>diffuse toxic goiter</kwd><kwd>thyreostatic therapy</kwd><kwd>imidazole</kwd><kwd>propylthiouracil</kwd><kwd>thyroid gland</kwd><kwd>thyrotoxicosis</kwd><kwd>hypothyroidism</kwd><kwd>thyroid-stimulating hormone receptor antibodies</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>диффузный токсический зоб</kwd><kwd>тиреостатическая терапия</kwd><kwd>имидазол</kwd><kwd>пропилтиоурацил</kwd><kwd>щитовидная железа</kwd><kwd>тиреотоксикоз</kwd><kwd>гипотиреоз</kwd><kwd>антитела к рецептору тиреотропного гормона</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Bartalena L., Pinchera A., Marcocci L. Management of Graves' ophthalmopathy: reality and perspectives. Endocr. Rev. 2000;21: 168-99.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Luton D., Le Gac I., Vuillard E., et al. Management of Graves' disease during pregnancy: the key role of fetal thyroid gland monitoring. J. Clin. Endocrinol. Metab. 2005;90:6093-98.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Айламазян Э.К., Потин В.В., Крихели И.О. и др. Щитовидная железа и репродукция. Мед. академический журнал. 2008;8(1):22-8.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Davis L.E., Lucas M.G., Hankins G.D, Roark M.L. Thyrotoxicosis complicating pregnancy. Am. J. Obstet. Gynecol. 1989;160:63-70.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Millar K.L, Wing D.A., Leung A.S., Coonings P.P. Low birth weight and preeclampsia in pregnancies complicated by hyperthyroidism. Obstet. Gynecol. 1994;84:946-49.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Башакин Н.Ф., Аксенов А.Н., Троицкая М.В. и др. Особенности неонатального периода у детей, родившихся у матерей с диффузным токсическим зобом различной степени компенсации. Рос. вестн. акушера-гинеколога. 2006;6:30-3.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>McKenzie J.M., Zakarija M. Fetal and neonatal hyperthyroidism and hypothyroidism due to maternal TSH receptor antibodies. Thyroid. 1992;2:155-59.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Логутова Л.С., Петрухин В.А., Бурумкулова Ф.Ф. и др. Тактика ведения и родоразрешения пациенток с тиреотоксикозом. Росс. вестн. акушера-гинеколога. 2006;6:37-43.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Azizi F. The safety and efficacy of antithyroid drugs. Expert. Opin. Drug Saf. 2006;5:107-16.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Cooper D.S., Laurberg P. Hyperthyroidism in pregnancy. Lancet Diabet. Endocrinol. 2013;1:238-49.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Laurberg P., Bournaud C., Karmisholt J., et al. Management of Graves' hyperthyroidism in pregnancy: focus on both maternal and fetal thyroid function, and caution against surgical thyroidectomy in pregnancy. Eur. J. Endocrinol. 2009;160:1-8.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Chan S., Kilby M.D. Thyroid hormone and central nervous system development. J. Endocrinol. 2000;165:1-8.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Laurberg P., Krejbjerg A., Andersen S.L. Relapse following antithyroid drug therapy for Graves' hyperthyroidism. Curr. Opin. Endocrinol. Diabetes. Obes. 2014;21:415-21.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Rivkees, S.A., Mattison D.R. Propylthiouracil (PTU) hepatoxicity in children and recommendations for discontinuation of use. Int. J. Pediatr. Endocrinol. 2009;13:2041.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Karlsson F., Axelssol O., Melhus H. Severe embriopathy and exposure to methimasole in early pregnancy. J. Clin. Endocrinol. Metab. 2002;87(2):947-48.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Andersen S.L., Olsen J., Wu C.S., et al. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. J. Clin. Endocrinol. Metab. 2013;9:4373-81.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Abraham P., Avenell A., McGeoch S.C., et al. Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database Syst. Rev. 2010;20( 1 ):CD003420.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Watanabe N., Narimatsu H., Noh J.Y., et al. Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves' disease. J. Clin. Endocrinol. Metab. 2012;97:E49-E53.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Bahn Chair R.S., Burch H.B., Cooper D.S., et al. Hyperthyroidism and other causes thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologist. Thyroid. 2011;21: 593-646.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Johansen K., Andersen A.N., Kampmann J.P., et al. Excretion of methimazole in human milk. J. Clin. Pharmacol. 1982;23:339-41.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Kampmann J.P., Johansen K., Hansen J.M., et al. Propylthiouracil in human milk. Revision of a dogma. Lancet. 1980;1:736-37.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>WHO/UNISEF/ICCIDD. Indicators for Assessing Iodine Deficiency Disorders and their Control Through Salt lodization. B.6. WHO/NUT. Geneva, 1994.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Brunn J., Block U., Ruf G., et al. Volumetrie der Schilddrüse mittels Real time-Sonogrophie. Dtsch. Med. Wochenschr. 1981;106:1338-40.</mixed-citation></ref></ref-list></back></article>
